Table 3.
Comparison of the association of serum urate and genetic urate score (per 100 umol/L) with serum urate, gout and cardiovascular risk factors in CHARGE cohorts.
| Serum Urate, per 100 umol/L | Genetic Urate Score, per 100 umol/L | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Age-Sex Adjusted∥ | Multivariable Adjusted# |
Multivariable Adjusted# | Detectable at 80% power** |
||||||
| Phenotype† | N/n Events | Beta* (Odds Ratio) |
P-value | Beta* (Odds Ratio) |
P-value | Beta* (Odds Ratio) |
995% CI | P-value | Beta* (Odds Ratio) |
| Serum Urate and Gout | |||||||||
| Serum Urate (umol/L) | 28220 | 100 | -- | 100 | -- | 99.3 | 95.0 , 103.7 | <5E-308 | 6.3 |
| Gout (odds ratio) | 25982/1033 | (2.35) | <0.001 | (2.1) | <0.001 | (12.4) | 8.5 , 18.0 | 3E-39 | (1.7) |
| CVD Risk Factors | |||||||||
| SBP (mm Hg)‡ | 28199 | 3.44 | <0.001 | 1.89 | <0.001 | −1.01 | −2.10 , 0.09 | 0.07 | 1.57 |
| SBP ( not treated; mmHg)§ | 20673 | 2.82 | <0.001 | 1.26 | <0.001 | −0.83 | −1.96 , 0.30 | 0.15 | 1.61 |
| DBP (mmHg)‡ | 28194 | 1.84 | <0.001 | 1.03 | <0.001 | −0.15 | −0.80 , 0.49 | 0.64 | 0.92 |
| DBP (not treated; mmHg)§ | 20669 | 1.67 | <0.001 | 0.78 | <0.001 | −0.34 | −1.04 , 0.35 | 0.33 | 0.99 |
| Fasting Glucose (mmol/l) | 25877 | 0.12 | <0.001 | −0.002 | 0.80 | −0.058 | −0.13 , 0.02 | 0.13 | 0.11 |
| Fasting Glucose (diabetes excluded, mmol/l) | 23726 | 0.14 | <0.001 | 0.09 | <0.001 | −0.0001 | −0.036 , 0.036 | 1.00 | 0.05 |
| Fasting Insulin (no DM) †† | 19899 | 35.84 | <0.001 | 20.22 | <0.001 | −0.015 | - | 0.99 | - |
| log eGFR (ml/min/1.73m2) | 23884 | −0.08 | <0.001 | −0.08 | <0.001 | 0.001 | −0.01 , 0.02 | 0.91 | −0.02 |
| CKD | 23387/3092 | (2.31) | <0.001 | (2.18) | <0.001 | (1.20) | 0.96 , 1.50 | 0.12 | (1.38) |
| Incident CHD | 23362/3050 | (1.23) | <0.001 | (1.09) | <0.001 | (1.03) | 0.85 , 1.25 | 0.76 | (1.32) |
To convert to mg/dl: Urate 100 umol/L = 1.68 mg/dl; glucose 1 mmol/l =18.18 mg/dl;
Beta coefficients and their standard errors were obtained from inverse variance weighted meta-analyses of individual study results.
For each phenotype, the analysis was restricted to those who had serum urate levels, all multivariable covariates and gene score available.
10 mm Hg was added to SBP if treated with antihypertensive medication, and 5 mm Hg to DBP if treated.
Individuals taking anti-hypertensive treatment were excluded from the analyses.
Adjusted for age, sex and study center/cohort where applicable
Covariates adjusted include: age, sex, BMI, alcohol consumption, antihypertensive medication for serum urate and gout; age, sex, BMI, SBP, antihypertensive medication, diabetes for eGFR and CKD; age,sex, BMI for blood pressure and glucose; and study center/site where applicable.
Effect Size detectable with 80% power in the current study with one-sided p-value ≤ 0.05.
Due to the lack of a standard to covert insulin in different studies to the same scale, sample size weighted meta analyses was performed instead. Z-statistics was reported in place for beta coefficient.